Malta - Engels - Medicines Authority

krka dd novo mesto Šmarješka cesta 6, 8501 novo mesto, slovenia - film-coated tablet - rosuvastatin 5 mg - lipid modifying agents

Malta - Engels - Medicines Authority

krka dd novo mesto Šmarješka cesta 6, 8501 novo mesto, slovenia - film-coated tablet - rosuvastatin 10 mg - lipid modifying agents

Malta - Engels - Medicines Authority

krka dd novo mesto Šmarješka cesta 6, 8501 novo mesto, slovenia - film-coated tablet - rosuvastatin 20 mg - lipid modifying agents

Malta - Engels - Medicines Authority

krka dd novo mesto Šmarješka cesta 6, 8501 novo mesto, slovenia - film-coated tablet - rosuvastatin 40 mg - lipid modifying agents

Malta - Engels - Medicines Authority

krka dd novo mesto novo mesto, Šmarješka cesta 6, 8501 novo mesto, slovenia - rosuvastatin - film-coated tablet - rosuvastatin 5 mg - lipid modifying agents

Malta - Engels - Medicines Authority

krka dd novo mesto novo mesto, Šmarješka cesta 6, 8501 novo mesto, slovenia - rosuvastatin - film-coated tablet - rosuvastatin 10 mg - lipid modifying agents

Malta - Engels - Medicines Authority

krka dd novo mesto novo mesto, Šmarješka cesta 6, 8501 novo mesto, slovenia - rosuvastatin - film-coated tablet - rosuvastatin 20 mg - lipid modifying agents

Malta - Engels - Medicines Authority

krka dd novo mesto novo mesto, Šmarješka cesta 6, 8501 novo mesto, slovenia - rosuvastatin - film-coated tablet - rosuvastatin 40 mg - lipid modifying agents

Australië - Engels - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - atorvastatin calcium trihydrate, quantity: 82.725 mg (equivalent: atorvastatin, qty 80 mg); ezetimibe, quantity: 10 mg - tablet, film coated - excipient ingredients: calcium carbonate; crospovidone; microcrystalline cellulose; hyprolose; lactose monohydrate; sodium lauryl sulfate; sodium stearylfumarate; colloidal anhydrous silica; povidone; lactose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - prevention of cardiovascular disease ezetimibe/atorvastatin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of atorvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy,primary hypercholesterolaemia ezetimibe/atorvastatin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: ? not appropriately controlled with atorvastatin or ezetimibe alone; or ? already treated with atorvastatin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh) ezetimibe/atorvastatin is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - atorvastatin calcium trihydrate, quantity: 10.341 mg (equivalent: atorvastatin, qty 10 mg); ezetimibe, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose; colloidal anhydrous silica; crospovidone; sodium lauryl sulfate; sodium stearylfumarate; microcrystalline cellulose; povidone; lactose monohydrate; calcium carbonate; hyprolose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - prevention of cardiovascular disease ezetimibe/atorvastatin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of atorvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy,primary hypercholesterolaemia ezetimibe/atorvastatin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: ? not appropriately controlled with atorvastatin or ezetimibe alone; or ? already treated with atorvastatin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh) ezetimibe/atorvastatin is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).